US Stock MarketDetailed Quotes

CING Cingulate

Watchlist

4.4522
-0.0578-1.28%

Trading Oct 15 15:02 ET

13.55MMarket Cap-13P/E (TTM)

Cingulate Stock Forum

Sign in to post a comment

$Cingulate (CING.US)$ drop down again

Trending News. 📊

$Cingulate (CING.US)$
via @Lnova 👌

Trending News. 📊

2

20

Lnova : thanks I am still trying to find out more about this. This article said that the study commenced but the news article before this one on $Cingulate (CING.US)$ page just said that that the last part of the study has been initiated. I mean I guess both are true if it happened and commenced but the articles were published back to back so I’m gonna try to find out more and see when results from the trials may be announced… will post that if I find anything

Report
Reply

Cancel Reply
Arrayfunction Lnova : I am a bit confused about the direction of the company. Their drug pipelines are compounds that already exist in both immediate and extended release formulations. They have a lot of PR on a "better" extended release mechanism? But I don't quite see why that is novel enough to take any market shares from the existing meds.
Especially since they are targeting far less popular stimulants (e.g. not Adderall, Vyvanse, Ritalin, etc) and aren't claiming any new features like reduced abuse potential. As someone who takes stimulants daily, I have zero reason to switch. The market space for ADHD meds would be finding a better non-stimulant drug, but that hasn't exactly been a great success (e.g. Qelbree)

Report
Reply

Cancel Reply
Lnova Arrayfunction : I feel you I take Adderall too. I think the new feature CING is wanting to bring with their medication is that there is somehow like multiple extended releases per dose. That’s the way I understood it. You know how there is XR but it only lasts so long? I guess CING is claiming theirs can release more than once throughout a dose, I have no idea how. And they said it’s to make the dose last longer and prevent side effect of crashing

Report
Reply

Cancel Reply
Arrayfunction : Oh wow. They are literally following the Purdue pharma playbook almost step for step. Purdue made virtually the exact same claims about oxycontin. Oxycontin's patent was only valid if it actually lasted more than 6-8 hours (which already existed on the market).
Oxycontin didn't actually last that long though. And the lawsuit proves they very much were aware of that. Which is why they sent their army of sales reps out to tell doctors to prescribe higher doses per pill (after they rightfully complained about it wearing off too soon) rather than multiple pills. Protected the patent over the patient.
I feel you on the dosing. I only get about 4ish hours from the 30 mg XR I take in the morning. But I just use 3 10mg IR tablets I am prescribed to take after that wears off to get me another 6-7 hours or so. It's another sad reality that I am extremely lucky to have a psych NP who trusts me to write prescriptions like that for me over the years. Most people won't. So they are pitching technology and huge cost to get around docs presuming guilty until innocent on patients abusing drugs

Report
Reply

Cancel Reply
Lnova Arrayfunction : yeah I feel you even Adderall XR dose doesn’t last that long. I used to be prescribed OxyContin too and know what you mean. Tbh I don’t know much about CING I just remember it ran one weekend from like $4 to $22 or so. So I keep an eye on it. There seemed to be a lot of support in the last run it had

Report
Reply

Cancel Reply

View more comments...

$Cingulate (CING.US)$ when are you going to fill the gap below?

$Cingulate (CING.US)$ 4 coming?

3

$Cingulate (CING.US)$ $5~4

1

$Cingulate (CING.US)$ drop to 5 dollars

4

$Cingulate (CING.US)$
Cool, was hoping it would bounce off 6 instead of dropping to 1.8.. Just watch out for sell block at 10.

1

1

$Cingulate (CING.US)$ wow💥💥💥

1

$Cingulate (CING.US)$ short volume decreasing, now we start marking our entry position .. wait a little

4

6

$Cingulate (CING.US)$ red for 3 days now

1

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

No Data